IL37 and psoriasis vulgaris: Another IL-23 blocker, guselkumab, approved for the treatment of plaque psoriasis and psoriatic arthritis, also has the potential to treat patients with Crohn’s disease [47,50,51,52,53,54] and ulcerative colitis [50,55,56,57].